Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes.
The FDA proposed the Nutrition Info box be placed somewhere in the top third of the principal display panel on the front of the package. The proposed rule does not include foods marketed toward ...